Market Cap 375.09M
Revenue (ttm) 4.83M
Net Income (ttm) 27.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 575.16%
Debt to Equity Ratio 0.00
Volume 12,300
Avg Vol 4,206
Day's Range N/A - N/A
Shares Out 24.17M
Stochastic %K 64%
Beta 1.07
Analysts Strong Buy
Price Target $46.00

Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 482 2333
Fax: 617 482 3337
Address:
6 Tide Street, Suite 400, Boston, United States
BioTuesdays
BioTuesdays Apr. 2 at 1:06 PM
$PRTC has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in generalized anxiety disorder (GAD). https://biotuesdays.com/2026/04/02/puretechs-seaport-reports-positive-data-from-trial-of-glyphago-in-gad/
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 2 at 12:21 PM
$PRTC (+3.6% pre) PureTech publishes phase 2b trial results for lung fibrosis drug https://ooc.bz/l/97914
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 9:42 PM
$PRTC RSI: 47.23, MACD: -0.2690 Vol: 0.45, MA20: 17.36, MA50: 17.75 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 8:06 PM
$PRTC RSI: 29.17, MACD: -0.1642 Vol: 0.61, MA20: 17.95, MA50: 17.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 27 at 10:31 AM
$PRTC trading at $19.06, with highs at $19.84 and lows at $13.49. Recent volume averaging 4,329, with last session at 1,900.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 8:38 PM
$PRTC RSI: 88.86, MACD: 0.4708 Vol: 0.80, MA20: 17.27, MA50: 16.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 10:45 PM
$PRTC Current Stock Price: $16.72
0 · Reply
ResonanceRadius
ResonanceRadius Dec. 25 at 5:22 PM
$PRTC This ticker is entering a stage where execution quality will overshadow headline narratives. Cost discipline must coexist with targeted investment. Smart capital allocation could unlock optionality not yet reflected. The thesis improves only as operational proof accumulates.
0 · Reply
BioTuesdays
BioTuesdays Dec. 18 at 4:43 PM
$PRTC has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately https://biotuesdays.com/2025/12/18/puretech-appoints-robert-lyne-as-ceo/
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 11 at 6:21 PM
0 · Reply
Latest News on PRTC
PureTech Appoints Robert Lyne as Chief Executive Officer

Dec 18, 2025, 2:00 AM EST - 3 months ago

PureTech Appoints Robert Lyne as Chief Executive Officer

PRTC


PureTech Health plc – Half-Year Report

Aug 28, 2025, 2:00 AM EDT - 7 months ago

PureTech Health plc – Half-Year Report

PRTC


PureTech Health: Notice of Half-Yearly Results

Aug 18, 2025, 2:00 AM EDT - 8 months ago

PureTech Health: Notice of Half-Yearly Results

PRTC


PureTech Announces Leadership Transition

Jul 16, 2025, 2:00 AM EDT - 9 months ago

PureTech Announces Leadership Transition

PRTC


PureTech Announces Board Change

Jul 8, 2025, 12:45 PM EDT - 9 months ago

PureTech Announces Board Change

PRTC


PureTech Health: Results of Annual General Meeting

Jun 16, 2025, 12:59 PM EDT - 10 months ago

PureTech Health: Results of Annual General Meeting

PRTC


PureTech Health: Notice of Results

Apr 23, 2025, 2:00 AM EDT - 1 year ago

PureTech Health: Notice of Results

PRTC


PureTech Appoints Peel Hunt as Joint UK Corporate Broker

Apr 9, 2025, 2:00 AM EDT - 1 year ago

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

PRTC


PureTech Health plc Statement Regarding Press Speculation

Apr 7, 2025, 12:16 PM EDT - 1 year ago

PureTech Health plc Statement Regarding Press Speculation

PRTC


PureTech Appoints UBS as UK Corporate Broker

Jan 6, 2025, 2:00 AM EST - 1 year ago

PureTech Appoints UBS as UK Corporate Broker

PRTC


PureTech to Present at CHEST 2024 Annual Meeting

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PureTech to Present at CHEST 2024 Annual Meeting

PRTC


PureTech Health plc – Half-Year Report

Aug 28, 2024, 2:01 AM EDT - 1 year ago

PureTech Health plc – Half-Year Report

PRTC


PureTech Health: Results of the Tender Offer

Jun 24, 2024, 2:00 AM EDT - 1 year ago

PureTech Health: Results of the Tender Offer

PRTC


PureTech Announces Change of Board Role

Jun 20, 2024, 2:00 AM EDT - 1 year ago

PureTech Announces Change of Board Role

PRTC


PureTech Health: Result of General Meeting

Jun 6, 2024, 12:38 PM EDT - 1 year ago

PureTech Health: Result of General Meeting

PRTC


BioTuesdays
BioTuesdays Apr. 2 at 1:06 PM
$PRTC has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in generalized anxiety disorder (GAD). https://biotuesdays.com/2026/04/02/puretechs-seaport-reports-positive-data-from-trial-of-glyphago-in-gad/
0 · Reply
OpenOutcrier
OpenOutcrier Apr. 2 at 12:21 PM
$PRTC (+3.6% pre) PureTech publishes phase 2b trial results for lung fibrosis drug https://ooc.bz/l/97914
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 9:42 PM
$PRTC RSI: 47.23, MACD: -0.2690 Vol: 0.45, MA20: 17.36, MA50: 17.75 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 8:06 PM
$PRTC RSI: 29.17, MACD: -0.1642 Vol: 0.61, MA20: 17.95, MA50: 17.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 27 at 10:31 AM
$PRTC trading at $19.06, with highs at $19.84 and lows at $13.49. Recent volume averaging 4,329, with last session at 1,900.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 8:38 PM
$PRTC RSI: 88.86, MACD: 0.4708 Vol: 0.80, MA20: 17.27, MA50: 16.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 10:45 PM
$PRTC Current Stock Price: $16.72
0 · Reply
ResonanceRadius
ResonanceRadius Dec. 25 at 5:22 PM
$PRTC This ticker is entering a stage where execution quality will overshadow headline narratives. Cost discipline must coexist with targeted investment. Smart capital allocation could unlock optionality not yet reflected. The thesis improves only as operational proof accumulates.
0 · Reply
BioTuesdays
BioTuesdays Dec. 18 at 4:43 PM
$PRTC has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately https://biotuesdays.com/2025/12/18/puretech-appoints-robert-lyne-as-ceo/
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 11 at 6:21 PM
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 8 at 1:47 PM
$PRTC (-8.1% pre) PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis https://ooc.bz/l/86630
0 · Reply
briefingcom
briefingcom Dec. 8 at 1:08 PM
$PRTC (-5.1%): PureTech Health advances deupirfenidone toward pivotal Phase 3 in idiopathic pulmonary fibrosis https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251208051736PRTC&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 5 at 1:11 PM
$PRTC Current Stock Price: $17.10 No options data available.
0 · Reply
nikitatrades
nikitatrades Oct. 5 at 1:48 PM
$PRTC's hub-and-spoke model spins out mature assets (Seaport, Gallop, Celea) to attract external capital, reducing parent R&D burn while retaining equity & royalties. This extends cash runway past 2028 and shifts funding risk to VCs. 🧬 #BiotechStrategy
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 7:20 PM
$PRTC Great piece that accurately captures PRTC's current position. So if you want to refresh your understanding of PRTC or learn about PRTC for the first time, this is essential reading. https://beyondspx.com/quote/PRTC/analysis/puretech-health-unlocking-value-through-de-risked-innovation-and-strategic-spin-outs-prtc
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Sep. 11 at 11:13 AM
$PRTC Puretech Founded Entity Seaport Therapeutics Doses First Participant In Phase 1 Study Of Glyphago SPT-320 Oral Prodrug Of Agomelatine For Generalized Anxiety Disorder
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 14 at 10:23 AM
WATCHLIST AUG 14 2025 $SRFM Surf Air Mobility And Electra Showcase Ultra Short Takeoff/Landing Hybrid-Electric Aircraft, Paving Way For New Direct Aviation Routes By 2029 $PRTC PureTech Health's Founded Entity, Vedanta Biosciences, Says Its Candidate VE202 Did Not Meet Primary Endpoint In Phase 2 COLLECTiVE202 Study For Treatment Of UC Patients $FOSL Fossil Group Announces Refinancing Of Its Debt Through A New $150M Asset-based Credit Facility With Ares Management $RIG Barclays Maintains Overweight on Transocean, Raises Price Target to $4 $BIVI BioVie To Present Poster Highlighting Design And Enrichment Strategy Of Its Ongoing Phase 2 ADDRESS-LC Trial At Keystone Symposia
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 26 at 12:23 PM
$VOR (+110.9% pre) $PRTC PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement https://ooc.bz/l/68777
0 · Reply
DonCorleone77
DonCorleone77 Jun. 26 at 10:17 AM
$PRTC $VOR PureTech Health founded entity Vor Bio enters license agreement with RemeGen PureTech Health (PRTC) noted that its founded entity, Vor Bio (VOR) and RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis. Under the terms of the agreement, Vor Bio will pay RemeGen an initial payment of $125M consisting of an upfront payment of $45M as well as $80M of warrants to purchase common stock with an exercise price of $0.0001 per share. The agreement also provides for potential regulatory and commercial milestones exceeding $4B, in addition to tiered royalties.
0 · Reply
PaulLaurent
PaulLaurent Jun. 26 at 7:38 AM
📈 4:00am EST Watchlist Addendum – June 26 $HIVE – Reported FY2025 revenue of $115.3M and net income of $56.2M. Mined 3,123 Bitcoin and continues expanding HPC and AI cloud infrastructure. Solid results may support more upside. $PRTC – As a founding stakeholder in Vor Bio, PRTC could benefit from the global license deal with RemeGen for VCAR33ALLO CAR-T. Sympathy play potential in biotech. $CTOR – Low float and early technical breakout structure. Being watched for multi-day run potential as volume builds. $LXRX – Possible multi-day runner. Recent volatility and momentum gaining attention from traders looking for continuation setups. $BDMD – After-hours runner. Price action and volume suggest it may be in play for intraday opportunities. ⚡ Market Tone: Biotech deals, strong earnings in crypto, and low-float momentum plays dominate the premarket addendum.
0 · Reply
TI7812
TI7812 Jun. 11 at 1:40 PM
$PRTC with this ultra thin trader this tweet will likely get some buying. no position, too thin. I don't know Dan's cost basis. this is the first time I've seen him tweet about this stock GTLA https://x.com/sharkbiotech/status/1932794091261034587
0 · Reply